Chapter 4: CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening

0Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Arguably, one of the most exciting new technologies for drug discovery in recent years has been that of CRISPR. The ability to efficiently silence or activate gene expression at genome scale using CRISPR/Cas vectors coupled with a lower false-positive rate than previous gene editing approaches has the potential to revolutionise the search for novel drug targets. Here we describe how this technology is transforming target identification, and what the future holds for the integration of genome editing into phenotypic drug discovery. We will guide readers through the process of applying CRISPR technology to phenotypic drug discovery, from project start to completion, describing key considerations and technological advances to maximise success.

Cite

CITATION STYLE

APA

Isherwood, B., Peel, S., Dunn, S., & McDermott, U. (2021). Chapter 4: CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening. In RSC Drug Discovery Series (Vol. 2021-January, pp. 58–82). Royal Society of Chemistry. https://doi.org/10.1039/9781839160721-00058

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free